Brug for hjælp fra en udbudsekspert? Se vores udbudsforberedelsestjeneste
Udbud

National infektions- og sepsis-audit – Akutte NHS-miljøer

Åben
Frist
28 dage tilbage
27. oktober 2026
Kontrakt detaljer
Kategori
Open Procedure
Reference
088832-2026
Værdi
£8,988,606
Lokation
United Kingdom, Storbritannien
Udgivet
21. september 2026
CPV-kode
Projekttidslinje

Udbud offentliggjort

18. september 2026

Frist for spørgsmål

20. oktober 2026

Frist for tilbud

27. oktober 2026

Kontraktens startdato

31. marts 2027

OrdregiverindsigtPRO
🔒
Lås op for ordregiverindsigt
Se forbrugsmønstre, foretrukne procedurer og mere.
Opgrader til Professionel →
Budget
£8,988,606
Varighed
36 måneder
Lokation
United Kingdom
Type
Open Procedure

Original udbudsbeskrivelse

The contract for the Infection and Sepsis Audit - Acute care settings (NISA-Acute) will initially be delivered for NHS-funded care in England and Wales for a period of three years, at a maximum total budget of up to £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. Bids exceeding these limits will be rejected. All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. The maximum budget ‘core’ value excludes the potential two year extension and aspirational intent as described in section 14.3 of Annex A - Service Specification. Please note, there is no commitment by the Authority at this stage to include any of the below aspirational intent. Taking this aspirational intent into account, including the possibility that a contract extension may be offered for an additional 24 months, the potential ceiling value is £8,988,606.00 GBP including VAT. This is a new national clinical audit for severe infection and sepsis in acute NHS hospital settings. The aim is to provide benchmarked infection and sepsis care data to identify variation and drive improvement over time. Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. While it is an unusual complication of developing an infection, it can be triggered by any infection. When people die from an infection, it is most commonly due to sepsis. Sepsis is complex and hard to diagnose, with no single test and symptoms that overlap with other conditions (NHS England Modern Service Framework, 2026) Severe infections may lead to the development of sepsis, particularly in at-risk groups, and are one of the most common reasons for emergency admission to hospital. Both infection and sepsis are major causes of morbidity and mortality in the UK, and costly to the NHS and wider economy: In 2025 there were over 23,000 deaths involving sepsis (Office for National Statistics). Patients and carers who we engaged with as part of specification development told us of long-term impacts that some sepsis survivors experience, from reduced mobility and cognitive difficulties, to loss of limbs or vision impairments. Each year, the NHS in England spends over £1billion on sepsis care, and over £6.5billion on infection care. Wider economic costs are estimated at £10-15billion annually (York Health Economics Consortium, 2017). 1,300 clinical negligence claims were made regarding sepsis from 2020/21 to 2024/25, costing £65.3m in litigation. Most claims relate to delays and failures in treatment and diagnosis. Several major healthcare initiatives have been launched to help improve care related to sepsis and severe infection, including: NHS England’s sepsis Modern Service Framework (MSF), which aims to reduce death, life-threatening complications and long-term impact from sepsis and severe infection by at least 25% by 2035, as well as reducing health inequalities (published July 2026). NHS England’s National Improvement Programme for ‘Optimising the acute management of sepsis’ (as part of the MSF activities). The National Patient Safety Plan for NHS Wales 2026-2031, which includes sepsis care. The UK Anti-Microbial Resistance (AMR) National Action Plan, which pledges to strengthen infection prevention and control (IPC) and antimicrobial stewardship (AMS) in health and social care settings New NICE guidelines for recognition, diagnosis and early management of suspected sepsis, published in November 2025 (NG253-NG255) Establishing the NISA-Acute audit is a key ambition of the NHS England sepsis MSF, and the audit will be expected to align closely with all the initiatives listed above. The audit funders have selected ‘early stages of care’ as the initial priority for this audit because this is a critical point for effective severe infection management and the swift identification and treatment of sepsis. Prompt, effective treatment is vital to improving outcomes, and both Prevention of Future Death (PFD) reports and Health Services Safety Investigations Body (HSSIB) investigations have highlighted opportunities to improve care in this area.

Risikoanalyse

Risikoanalyse er endnu ikke tilgængelig for dette lands udbud. I øjeblikket understøttet: Estland, Letland, Litauen, Polen, Frankrig, Storbritannien, Danmark, Holland, Norge og Finland.

Vinderstrategi

Få en AI-drevet vinderstrategi skræddersyet til dette udbud. Inkluderer sandsynlighedsscore for at vinde, vigtige muligheder og udfordringer, anbefalede fokusområder for tilbuddet, indsigt i konkurrencepositionering og handlingsrettede anbefalinger for at maksimere dine chancer.

Log ind

Konkurrenter

Opgrader for at se, hvilke virksomheder der sandsynligvis vil afgive tilbud på dette udbud, baseret på historiske indkøbsdata.

Log ind

Krav og kvalifikationer

AI udtrækker og organiserer alle krav fra udbudsdokumenter — obligatoriske kvalifikationer, tekniske specifikationer, finansielle betingelser og indsendelsesregler — tydeligt kategoriseret, så du ved præcis, hvad der kræves for at byde.

Log ind

Grundlæggende krav

  • Company registration in EU required
  • Proven track record in similar projects
  • Financial stability documentation

Dokumenter

3 dokumenter tilgængelige med AI-resuméer

OCDS RecordDOC
088832-2026_ocds_record.json

Intet resumé tilgængeligt for dette dokument.

Vis
OCDS Release PackageDOC
088832-2026_ocds_release.json

Intet resumé tilgængeligt for dette dokument.

Vis
Official PDF VersionPDF
088832-2026_official.pdf

Intet resumé tilgængeligt for dette dokument.

Vis

Forhåndsvisning af Dokumenter

Tilmeld dig for at se dokumentresuméer og analyser

Kvalitetsscore

Omfattende kvalitetsanalyse af dette udbud, der scorer juridisk overholdelse, klarhed, fuldstændighed, retfærdighed, praktisk anvendelighed, datakonsistens og bæredygtighed på en skala fra 0-100 med detaljeret opdeling og anbefalinger.

Log ind